Oligschlaeger Y - Search Results

1

Inflammatory Bowel Disease: A Stressed "Gut/Feeling".

Oligschlaeger Y, Yadati T, Houben T, Condello Oliván CM, Shiri-Sverdlov R. Oligschlaeger Y, et al. Cells. 2019 Jun 30;8(7):659. doi: 10.3390/cells8070659. Cells. 2019. PMID: 31262067 Free PMC article. Review.

2

Hematopoietic Npc1 mutation shifts gut microbiota composition in Ldlr^-/- mice on a high-fat, high-cholesterol diet.

Houben T, Penders J, Oligschlaeger Y, Dos Reis IAM, Bonder MJ, Koonen DP, Fu J, Hofker MH, Shiri-Sverdlov R. Houben T, et al. Among authors: oligschlaeger y. Sci Rep. 2019 Oct 18;9(1):14956. doi: 10.1038/s41598-019-51525-x. Sci Rep. 2019. PMID: 31628414 Free PMC article.

3

Nonalcoholic Fatty Liver Disease.

Ding L, Oligschlaeger Y, Shiri-Sverdlov R, Houben T. Ding L, et al. Among authors: oligschlaeger y. Handb Exp Pharmacol. 2022;270:233-269. doi: 10.1007/164_2020_352. Handb Exp Pharmacol. 2022. PMID: 32185502 Review.

4

MSP is a negative regulator of inflammation and lipogenesis in ex vivo models of non-alcoholic steatohepatitis.

Chanda D, Li J, Oligschlaeger Y, Jeurissen ML, Houben T, Walenbergh SM, Shiri-Sverdlov R, Neumann D. Chanda D, et al. Among authors: oligschlaeger y. Exp Mol Med. 2016 Sep 9;48(9):e258. doi: 10.1038/emm.2016.79. Exp Mol Med. 2016. PMID: 27609031 Free PMC article.

5

Prevention of oxLDL uptake leads to decreased atherosclerosis in hematopoietic NPC1-deficient Ldlr^-/- mice.

Jeurissen MLJ, Walenbergh SMA, Houben T, Gijbels MJJ, Li J, Hendrikx T, Oligschlaeger Y, van Gorp PJ, Binder CJ, Donners MMPC, Shiri-Sverdlov R. Jeurissen MLJ, et al. Among authors: oligschlaeger y. Atherosclerosis. 2016 Dec;255:59-65. doi: 10.1016/j.atherosclerosis.2016.10.038. Epub 2016 Oct 20. Atherosclerosis. 2016. PMID: 27816810 Free article.

6

Exogenously Added Oxyphytosterols Do Not Affect Macrophage-Mediated Inflammatory Responses.

Oligschlaeger Y, Houben T, Jeurissen MLJ, Bitorina AV, Konings M, Baumgartner S, Plat J, Shiri-Sverdlov R. Oligschlaeger Y, et al. Lipids. 2018 Apr;53(4):457-462. doi: 10.1002/lipd.12044. Epub 2018 May 10. Lipids. 2018. PMID: 29746008

7

Inhibiting Extracellular Cathepsin D Reduces Hepatic Steatosis in Sprague⁻Dawley Rats ^†.

Khurana P, Yadati T, Goyal S, Dolas A, Houben T, Oligschlaeger Y, Agarwal AK, Kulkarni A, Shiri-Sverdlov R. Khurana P, et al. Among authors: oligschlaeger y. Biomolecules. 2019 May 4;9(5):171. doi: 10.3390/biom9050171. Biomolecules. 2019. PMID: 31060228 Free PMC article.

8

Plasma cathepsin D activity is negatively associated with hepatic insulin sensitivity in overweight and obese humans.

Ding L, Goossens GH, Oligschlaeger Y, Houben T, Blaak EE, Shiri-Sverdlov R. Ding L, et al. Among authors: oligschlaeger y. Diabetologia. 2020 Feb;63(2):374-384. doi: 10.1007/s00125-019-05025-2. Epub 2019 Nov 5. Diabetologia. 2020. PMID: 31690989 Free PMC article.

9

NAFLD Preclinical Models: More than a Handful, Less of a Concern?

Oligschlaeger Y, Shiri-Sverdlov R. Oligschlaeger Y, et al. Biomedicines. 2020 Feb 8;8(2):28. doi: 10.3390/biomedicines8020028. Biomedicines. 2020. PMID: 32046285 Free PMC article. Review.

10

Myosteatosis in NAFLD patients correlates with plasma Cathepsin D.

Ding L, De Munck TJI, Oligschlaeger Y, Dos Reis IM, Verbeek J, Koek GH, Houben T, Shiri-Sverdlov R. Ding L, et al. Among authors: oligschlaeger y. Biomol Concepts. 2021 May 15;12(1):27-35. doi: 10.1515/bmc-2021-0004. Biomol Concepts. 2021. PMID: 33991468 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

29 results

Search Page